Shopping Cart

BeiGene Ltd (BGNE)-Pharmaceuticals & Healthcare-Deals and Alliances Profile

SKU
GDPH2476617D
READ MORE
USD 250
Single User License
USD 250
Site License
USD 500
Corporate User License
USD 750

BeiGene Ltd (BeiGene) is a biopharmaceutical company that focuses on the discovery and development of molecularly targeted and immuno-oncology drugs for the treatment of cancer. Its lead product candidates include BGB-3111, a highly selective sm

READ MORE
  • Details
  • Table Of Content
  • Licence Rights
  • Section Purchase
  • Products and Companies

BeiGene Ltd (BeiGene) is a biopharmaceutical company that focuses on the discovery and development of molecularly targeted and immuno-oncology drugs for the treatment of cancer. Its lead product candidates include BGB-3111, a highly selective small molecule BTK inhibitor for the treatment of lymphoma; and BGB-A317, a monoclonal antibody against the immune checkpoint receptor PD-1. BeiGene's other pipeline products include BGB-290, BGB-283, a PD-L1 monoclonal antibody, a TIM-3 cell surface protein monoclonal antibody, a next generation RAF dimer inhibitor, and candidates from several undisclosed preclinical immuno-oncology programs. The company also has a cancer biology platform that addresses the value of primary tumor biopsies in developing new cancer models. It has operations in China, the US, Australia and New Zealand. BeiGene is headquartered in Beijing, China.

BeiGene Ltd (BGNE)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

Business Description-A brief description of the company's operations.

Key Employees-A list of the key executives of the company.

Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

Key Competitors-A list of the key competitors of the company.

Key Recent Developments-A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

READ MORE

Scope

Table of Contents

Table of Contents 2

List of Tables 4

List of Figures 5

BeiGene Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6

BeiGene Ltd, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 7

BeiGene Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8

BeiGene Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 9

BeiGene Ltd, Medical Devices Deals, 2011 to YTD 2017 10

BeiGene Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 11

BeiGene Ltd, Pharmaceuticals & Healthcare, Deal Details 13

Venture Financing 13

BeiGene Raises USD98.1 Million in Venture Financing 13

BeiGene Raises USD73.2 Million in Venture Financing 13

BeiGene Plans To Raise Up To US$150 Million In Financing 14

BeiGene Receives Investment From Merck Sharp & Dohme 15

Partnerships 15

Myriad Genetics Enters into Development Agreement with Beigene 15

Cancer Genetics Enters into Agreement with BeiGene 16

BeiGene Enters into Agreement with BioBAY 17

Licensing Agreements 17

Merck Serono Amends its Licensing Agreement with BeiGene for BeiGene-283 17

BeiGene Enters Into Licensing Agreement With Janssen Pharmaceutica For Intetumumab 18

BeiGene Enters Into Licensing Agreement With Janssen Pharmaceutica For MTKi-327 19

Equity Offering 20

BeiGene Raises USD200 Million in Public Offering of American Depositary Shares 20

BeiGene Raises USD182.2 Million in IPO of ADS 22

BeiGene Raises USD97.4 Million in Private Placement of Series A-2 Preferred Stock 23

BeiGene Raises USD74.5 Million in Private Placement of Series A Preferred Stock 24

Debt Offering 25

BeiGene Raises USD3 Million in Private Placement of Notes 25

BeiGene Ltd-Key Competitors 27

Key Employees 28

Locations And Subsidiaries 30

Head Office 30

Other Locations & Subsidiaries 30

Recent Developments 31

Financial Announcements 31

Mar 22, 2017: BeiGene Reports Fourth Quarter and Full Year 2016 Financial Results 31

Nov 10, 2016: BeiGene Reports Third Quarter 2016 Financial Results 33

Aug 10, 2016: BeiGene Reports Second Quarter 2016 Financial Results 35

May 11, 2016: BeiGene Reports First Quarter 2016 Financial Results 37

Mar 30, 2016: BeiGene Reports Fourth Quarter and Full Year 2015 Financial Results 39

Corporate Communications 41

Sep 06, 2016: BeiGene Appoints Jane Huang, M.D. as Chief Medical Officer, Hematology 41

Aug 24, 2016: BeiGene Appoints Amy Peterson, M.D. as Chief Medical Officer, Immuno-oncology 42

Apr 11, 2016: BeiGene Appoints Eric Hedrick, M.D. as Interim Chief Medical Officer 43

Product Approvals 44

Mar 07, 2016: BeiGene Receives Approval to Initiate Clinical Trials in China With BGB-3111 44

Clinical Trials 45

Nov 11, 2016: BeiGene Presents Updated Clinical Data on PD-1 Antibody BGB-A317 in Patients with Advanced Solid Tumors at the Society for Immunotherapy of Cancer 31st Annual Meeting 45

Nov 03, 2016: BeiGene Announces Oral Presentations on BTK Inhibitor BGB-3111 at the 2016 American Society of Hematology Annual Meeting 47

Oct 07, 2016: BeiGene Presents Updated Clinical Data on BTK Inhibitor BGB-3111 in Patients with Waldenstrom's Macroglobulinemia at 9th International Workshop on Waldenstrom's Macroglobulinemia 48

Oct 04, 2016: BeiGene to Host Conference Call on BGB-3111 Data Presentation at IWWM-9 49

Oct 04, 2016: BeiGene to Present Updated BGB-A317 Data at the 2016 SITC Annual Meeting 50

Sep 11, 2016: BeiGene Receives Approval to Initiate Clinical Trials in China with PD-1 Antibody BGB-A317 51

Aug 18, 2016: BeiGene Receives Approval to Initiate Clinical Trials in China with PARP Inhibitor BGB-290 52

Jul 05, 2016: BeiGene Announces First Patient Dosing for Investigational BTK Inhibitor BGB-3111 in China 53

Jun 29, 2016: BeiGene Announces Initiation of a Combination Trial of the BTK Inhibitor BGB-3111 with the PD-1 Antibody BGB-A317 54

Jun 05, 2016: BeiGene Presents Initial Clinical Data on PD-1 Antibody BGB-A317 at the 2016 American Society of Clinical Oncology Annual Meeting 55

May 19, 2016: BeiGene Announces Presentation on BGB-A317 at the 2016 American Society of Clinical Oncology Annual Meeting 57

Apr 17, 2016: BeiGene Presents Clinical Data for RAF Dimer Inhibitor BGB-283 at the 2016 American Association for Cancer Research Annual Meeting 58

Mar 16, 2016: BeiGene Announces Presentations on BGB-283 and Other Pipeline Agents at the 2016 American Association for Cancer Research Annual Meeting 60

Jan 08, 2016: U.S. IND Becomes Active for BGB-A317, an Anti-PD-1 Monoclonal Antibody 61

Appendix 62

Methodology 62

About GlobalData 62

Contact Us 62

Disclaimer 62


List Of Figure

List of Figures

BeiGene Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2011 to YTD 2017 1

BeiGene Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 1

BeiGene Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 1

BeiGene Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 1

BeiGene Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6

BeiGene Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2011 to YTD 2017 7

BeiGene Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8

BeiGene Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 9

BeiGene Ltd, Medical Devices Deals, 2011 to YTD 2017 10


List Of Table

List of Tables

BeiGene Ltd, Pharmaceuticals & Healthcare, Key Facts 1

BeiGene Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6

BeiGene Ltd, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 7

BeiGene Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8

BeiGene Ltd, Deals By Therapy Area, 2011 to YTD 2017 9

BeiGene Ltd, Medical Devices Deals, 2011 to YTD 2017 10

BeiGene Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 11

BeiGene Raises USD98.1 Million in Venture Financing 13

BeiGene Raises USD73.2 Million in Venture Financing 13

BeiGene Plans To Raise Up To US$150 Million In Financing 14

BeiGene Receives Investment From Merck Sharp & Dohme 15

Myriad Genetics Enters into Development Agreement with Beigene 15

Cancer Genetics Enters into Agreement with BeiGene 16

BeiGene Enters into Agreement with BioBAY 17

Merck Serono Amends its Licensing Agreement with BeiGene for BeiGene-283 17

BeiGene Enters Into Licensing Agreement With Janssen Pharmaceutica For Intetumumab 18

BeiGene Enters Into Licensing Agreement With Janssen Pharmaceutica For MTKi-327 19

BeiGene Raises USD200 Million in Public Offering of American Depositary Shares 20

BeiGene Raises USD182.2 Million in IPO of ADS 22

BeiGene Raises USD97.4 Million in Private Placement of Series A-2 Preferred Stock 23

BeiGene Raises USD74.5 Million in Private Placement of Series A Preferred Stock 24

BeiGene Raises USD3 Million in Private Placement of Notes 25

BeiGene Ltd, Key Competitors 27

BeiGene Ltd, Key Employees 28

BeiGene Ltd, Other Locations 30

BeiGene Ltd, Subsidiaries 30

To know more information on Purchase by Section, please send a mail to

Brand Description
History Color sit amet, consectetur adipiscing elit. In gravida pellentesque ligula, vel eleifend turpis blandit vel. Nam quis lorem ut mi mattis ullamcorper ac quis dui. Vestibulum et scelerisque ante, eu sodales mi. Nunc tincidunt tempus varius. Integer ante dolor, suscipit non faucibus a, scelerisque vitae sapien.